PubRank

Kipp Weiskopf

Author PubWeight™ 22.94‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A 2012 4.20
2 Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med 2010 2.79
3 Asterless is a scaffold for the onset of centriole assembly. Nature 2010 2.51
4 CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood 2010 2.06
5 Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest 2012 1.92
6 Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma. Proc Natl Acad Sci U S A 2012 1.86
7 Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response. Proc Natl Acad Sci U S A 2013 1.68
8 Targeting CD137 enhances the efficacy of cetuximab. J Clin Invest 2014 1.29
9 A nonpeptidic cathepsin S activity-based probe for noninvasive optical imaging of tumor-associated macrophages. Chem Biol 2012 1.27
10 Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growth. Proc Natl Acad Sci U S A 2013 1.06
11 CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer. J Clin Invest 2016 0.92
12 A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells. MAbs 2015 0.82
13 Flipping the script on macrophages in leiomyosarcoma. Oncoimmunology 2012 0.82
14 Use of a KIT-specific monoclonal antibody to bypass imatinib resistance in gastrointestinal stromal tumors. Oncoimmunology 2013 0.77
15 Q&A: Michael Bishop. Free thinker. Nature 2014 0.75